|
The said drug is equivalent to reference listed drug, Carafate tablets. Sucralfate is used to treat and prevent ulcers in the intestines by forming a coating over ulcers, protecting the area from further injury. This helps ulcers heal more quickly.
The drug will be manufactured at the group's topical manufacturing facility at SEZ, Ahmedabad (India).
According to IQVIA MAT February 2023, Sucralfate Tablets USP, 1 gram had annual sales of $84 million in the United States.
The group now has 367 approvals and has so far filed over 440 ANDAs since the commencement of the filing process in FY 2003-04.
Zydus Lifesciences is a discovery-driven, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies.
The company's consolidated net profit jumped 24.5% to Rs 622.90 crore on 17.9% rise in net sales to Rs 4,159.80 crore in Q3 FY23 over Q3 FY22.
The scrip fell 0.41% to currently trade at Rs 517.75 on the BSE.
|